Shopping Cart 0
Cart Subtotal
USD 0

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Pipeline Review, H2 2017

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 3500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 7000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 10500
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Pipeline Review, H2 2017

Summary

According to the recently published report 'Macrophage Colony Stimulating Factor 1 Receptor-Pipeline Review, H2 2017'; Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) pipeline Target constitutes close to 36 molecules. Out of which approximately 34 molecules are developed by companies and remaining by the universities/institutes.

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Macrophage colony-stimulating factor (M-CSF) is a secreted cytokine which influences hematopoietic stem cells to differentiate into macrophages or other related cell types. It plays an essential role in the regulation of survival, proliferation and differentiation of hematopoietic precursor cells, especially mononuclear phagocytes, such as macrophages and monocytes. It promotes the release of pro-inflammatory chemokines, and thereby plays an important role in innate immunity and in inflammatory processes. It plays an important role in the regulation of osteoclast proliferation and differentiation, the regulation of bone resorption, and is required for normal bone development. It required for normal male and female fertility. It promotes reorganization of the actin cytoskeleton, regulates formation of membrane ruffles, cell adhesion and cell migration.

The report 'Macrophage Colony Stimulating Factor 1 Receptor-Pipeline Review, H2 2017' outlays comprehensive information on the Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 1, 2, 7, 8, 10 and 3 respectively. Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Oncology, Musculoskeletal Disorders, Central Nervous System, Gastrointestinal, Genetic Disorders, Immunology, Genito Urinary System And Sex Hormones, Respiratory and Undisclosed which include indications Solid Tumor, Ovarian Cancer, Breast Cancer, Epithelial Ovarian Cancer, Metastatic Melanoma, Bladder Cancer, Fallopian Tube Cancer, Gastric Cancer, Melanoma, Peritoneal Cancer, Pigmented Villonodular Synovitis, Recurrent Glioblastoma Multiforme (GBM), Tenosynovial Giant Cell Tumor, Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Bile Duct Cancer (Cholangiocarcinoma), Colorectal Cancer, Gastrointestinal Stromal Tumor (GIST), Head And Neck Cancer Squamous Cell Carcinoma, Metastatic Breast Cancer, Metastatic Colorectal Cancer, Non-Small Cell Lung Cancer, Pancreatic Cancer, Soft Tissue Sarcoma, Acral Lentiginous Melanoma, Follicular Thyroid Cancer, Gallbladder Cancer, Glioblastoma Multiforme (GBM), Inflammation, Medullary Thyroid Cancer, Metastatic Adenocarcinoma of The Pancreas, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Metastatic Ovarian Cancer, Papillary Thyroid Cancer, Renal Cell Carcinoma, Thyroid Cancer, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Adenocarcinoma, Adenocarcinoma Of The Gastroesophageal Junction, Alzheimer's Disease, Amyotrophic Lateral Sclerosis, Anaplastic Thyroid Cancer, Angiosarcoma, Asthma, Bone Metastasis, Brenner Tumor, Charcot-Marie-Tooth Disease Type I, Chondrosarcoma, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Crohn's Disease (Regional Enteritis), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), Endometrial Cancer, Ewing Sarcoma, Extrahepatic Bile Duct Cancer, Gliosarcoma, Hematological Tumor, Lentigo Maligna Melanoma, Liposarcoma, Lung Adenocarcinoma, Malignant Ascites, Malignant Mesothelioma, Merkel Cell Carcinoma, Metastatic Bile Duct Cancer, Metastatic Biliary Tract Cancer, Metastatic Pancreatic Cancer, Metastatic Renal Cell Carcinoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Disorders, Neuroblastoma, Neuroendocrine Tumors, Neuroinflammation, Non-Hodgkin Lymphoma, Non-Small Cell Lung Carcinoma, Osteolysis, Osteosarcoma, Pancreatic Ductal Adenocarcinoma, Paraganglioma (Glomus Jugulare Tumor), Peripheral Nerve Sheath Tumor (Neurofibrosarcoma), Peripheral T-Cell Lymphomas (PTCL), Pheochromocytoma, Post-Polycythemia Vera Myelofibrosis (PPV-MF), Primary Progressive Multiple Sclerosis (PPMS), Progressive Supranuclear Palsy, Prostate Cancer, Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Relapsing Remitting Multiple Sclerosis (RRMS), Renal Failure, Rhabdomyosarcoma, Salivary Gland Cancer, Sarcomas, Secondary Progressive Multiple Sclerosis (SPMS), Squamous Non-Small Cell Lung Cancer, Systemic Mastocytosis, Transitional Cell Carcinoma (Urothelial Cell Carcinoma), Unspecified, Uveal Melanoma and Von Hippel-Lindau Syndrome.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

The report reviews Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics and enlists all their major and minor projects

The report assesses Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) targeted therapeutics

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it?s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

READ MORE

Table Of Content

Scope

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Overview

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Companies Involved in Therapeutics Development

AB Science SA

Amgen Inc

Array BioPharma Inc

BCI Pharma

Bristol-Myers Squibb Co

CrystalGenomics Inc

CTI BioPharma Corp

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

GigaGen Inc

Hutchison MediPharma Ltd

Ignyta Inc

Nerviano Medical Sciences Srl

Novartis AG

Pfizer Inc

Plexxikon Inc

SignalChem Lifesciences Corp

Syndax Pharmaceuticals Inc

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Drug Profiles

AMG-820-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ARRY-382-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atezolizumab + emactuzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BLZ-945-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cabiralizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCBX-02-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DCC-3014-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ELB-041-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

emactuzumab + RG-7876-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

GW-2580-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HMPL-012-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-3022855-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

masitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Monoclonal Antibodies to Antagonize CSF1R for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MSB-015-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NMSP-088-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pacritinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pazopanib hydrochloride + pembrolizumab-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-0360324-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

pexidartinib hydrochloride-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-5622-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-73086-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PLX-7486-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PRV-6527-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RXDX-105-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize CSF1R for Oncology and Neuroinflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Antagonize FLT3 and CSF1R for AML and Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Inhibitor CSF1R for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CSF-1 Receptor for Oncology-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Antagonize CSF-1R for Inflammation-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Target CSF-1R for Unspecified Indication-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SNDX-6352-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sunitinib malate-Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Dormant Products

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Discontinued Products

Macrophage Colony Stimulating Factor 1 Receptor (CSF 1 Receptor or Proto Oncogene c Fms or CD115 or CSF1R or EC 2.7.10.1)-Product Development Milestones

Featured News & Press Releases

Nov 21, 2017: Preclinical data published in Nature Communications shows that masitinib is capable of counteracting resistance to oncology treatments, including gemcitabine

Nov 16, 2017: Pfizer Receives FDA Approval For Sutent (Sunitinib Malate) as First and Only Adjuvant Treatment for Adult Patients at High Risk of Recurrent Renal Cell Carcinoma

Nov 13, 2017: Array BioPharma Reports Initial Results From Novel Immunotherapy Combination At The Society For Immunotherapy Of Cancer 32nd Annual Meeting

Nov 11, 2017: Syndax Announces Presentation of Clinical Trial Data on Drug Candidate SNDX-6352 at Society for Immunotherapy of Cancer 32nd Annual Scientific Meeting

Nov 09, 2017: Bristol-Myers Squibb and Five Prime Present Phase 1a/1b Data Evaluating Cabiralizumab (anti-CSF-1 receptor antibody) with Opdivo (nivolumab) in Patients with Advanced Solid Tumors

Nov 07, 2017: Five Prime Therapeutics to Host Conference Call on November 8 to Review Cabiralizumab Phase 1a/1b Data

Nov 07, 2017: Syndax to Present Data On Drug Candidate SNDX-6352 at SITC 32nd Annual Scientific Meeting

Oct 31, 2017: Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor

Oct 19, 2017: Preclinical data showing protective effect of masitinib on the peripheral nervous system in ALS published in the Journal of Clinical Investigation Insight

Oct 11, 2017: Five Prime Announces Cabiralizumab Phase 1a/1b Data Abstract Selected for Late Breaking Oral Presentation at the Society for Immunotherapy of Cancer 32nd Annual Meeting

Sep 28, 2017: AB Science announces that abstracts reporting on clinical and preclinical data of masitinib in the treatment of ALS, have been selected for presentation at 6 major international meetings during 2017

Sep 19, 2017: Pfizer Announces Outcome of FDA Advisory Committee Meeting for SUTENT in Patients at High Risk of Recurrent Renal Cell Carcinoma After Surgery

Sep 14, 2017: AB Science announces that CHMP adopted a negative opinion for masitinib marketing authorization in indolent systemic mastocytosis after reassessment

Sep 11, 2017: Ignyta Provides Update on Investigational Lung Cancer Drug RXDX-105 at ESMO 2017 Congress

Sep 07, 2017: Ignyta Announces Presentation of New Phase 1B Clinical Data on RXDX-105 in RET Fusion-Positive NSCLC at ESMO 2017 Congress

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer


List Of Figure

List of Figures

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Top 10 Indications, H2 2017

Number of Products by Mechanism of Actions, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Top 10 Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017


List Of Table

List of Tables

Number of Products under Development by Stage of Development, H2 2017

Number of Products under Development by Therapy Areas, H2 2017

Number of Products under Development by Indications, H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..3), H2 2017

Number of Products under Development by Indications, H2 2017 (Contd..4), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1)

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Companies, H2 2017 (Contd..3), H2 2017

Products under Development by Companies, H2 2017 (Contd..4), H2 2017

Products under Development by Companies, H2 2017 (Contd..5), H2 2017

Products under Development by Companies, H2 2017 (Contd..6), H2 2017

Products under Development by Companies, H2 2017 (Contd..7), H2 2017

Products under Development by Companies, H2 2017 (Contd..8), H2 2017

Products under Development by Companies, H2 2017 (Contd..9), H2 2017

Products under Development by Companies, H2 2017 (Contd..10), H2 2017

Number of Products under Investigation by Universities/Institutes, H2 2017

Products under Investigation by Universities/Institutes, H2 2017

Number of Products by Stage and Mechanism of Actions, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Pipeline by AB Science SA, H2 2017

Pipeline by Amgen Inc, H2 2017

Pipeline by Array BioPharma Inc, H2 2017

Pipeline by BCI Pharma, H2 2017

Pipeline by Bristol-Myers Squibb Co, H2 2017

Pipeline by CrystalGenomics Inc, H2 2017

Pipeline by CTI BioPharma Corp, H2 2017

Pipeline by Deciphera Pharmaceuticals LLC, H2 2017

Pipeline by Eli Lilly and Co, H2 2017

Pipeline by Elsalys Biotech SAS, H2 2017

Pipeline by F. Hoffmann-La Roche Ltd, H2 2017

Pipeline by GigaGen Inc, H2 2017

Pipeline by Hutchison MediPharma Ltd, H2 2017

Pipeline by Ignyta Inc, H2 2017

Pipeline by Nerviano Medical Sciences Srl, H2 2017

Pipeline by Novartis AG, H2 2017

Pipeline by Pfizer Inc, H2 2017

Pipeline by Plexxikon Inc, H2 2017

Pipeline by SignalChem Lifesciences Corp, H2 2017

Pipeline by Syndax Pharmaceuticals Inc, H2 2017

Dormant Products, H2 2017

Dormant Products, H2 2017 (Contd..1), H2 2017

Dormant Products, H2 2017 (Contd..2), H2 2017

Dormant Products, H2 2017 (Contd..3), H2 2017

Dormant Products, H2 2017 (Contd..4), H2 2017

Dormant Products, H2 2017 (Contd..5), H2 2017

Dormant Products, H2 2017 (Contd..6), H2 2017

Discontinued Products, H2 2017

Discontinued Products, H2 2017 (Contd..1), H2 2017

Discontinued Products, H2 2017 (Contd..2), H2 2017

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License: 
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:  
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies


Companies

AB Science SA

Amgen Inc

Array BioPharma Inc

BCI Pharma

Bristol-Myers Squibb Co

CrystalGenomics Inc

CTI BioPharma Corp

Deciphera Pharmaceuticals LLC

Eli Lilly and Co

Elsalys Biotech SAS

F. Hoffmann-La Roche Ltd

GigaGen Inc

Hutchison MediPharma Ltd

Ignyta Inc

Nerviano Medical Sciences Srl

Novartis AG

Pfizer Inc

Plexxikon Inc

SignalChem Lifesciences Corp

Syndax Pharmaceuticals Inc